Jupiter Endovascular today shared findings from the SPIRARE II pivotal trial evaluating its Vertex pulmonary embolectomy ...
SAINT PAUL, Minn.--(BUSINESS WIRE)--Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary ...
Vertex Pulmonary Embolectomy System demonstrated significant right heart recovery, low adverse event rates, and reproducible performance across high-severity PE patients Jupiter Endovascular, Inc.
Data from Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) when added to background therapy in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the SPIRARE II trial set to evaluate the use of Jupiter Endovascular’s Vertex Pulmonary ...
Preterm birth is a lifelong cardiopulmonary risk marker, with markedly higher cardiovascular disease and heart failure risk ...
Oura Ring is adding support for cardiovascular age and cardio capacity. Cardiovascular age collects 14 days of data to tell you how your heart health aligns with your chronological age. Cardio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results